Semaglutide vs. Tirzepatide
This is the rare peptide comparison with real head-to-head evidence. Both molecules are FDA-approved, both went through massive trial programs, and a direct comparison trial (SURMOUNT-5) has actually been run — so the honest answer here is unusually specific.
Semaglutide (Ozempic, Wegovy) activates the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) activates GLP-1 and GIP receptors together. Both slow stomach emptying, signal fullness, and improve glycemic control; the second receptor is tirzepatide's bet, and the trial data suggests the bet pays.
The facts, side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Regulatory status | FDA-approved drug | FDA-approved drug |
| Evidence level | Human clinical trials | Human clinical trials |
| Category | Weight Loss | Weight Loss |
Full profiles: Semaglutide · Tirzepatide
Average weight loss in trials
In SURMOUNT-5, the head-to-head trial in adults with obesity, average weight loss was greater with tirzepatide than semaglutide (roughly 20% vs 14% over 72 weeks). Averages are not personal predictions — responses spread widely around them in both arms.
Evidence maturity
Semaglutide has the longer record: more years on market, cardiovascular-outcome trials completed, enormous real-world exposure. Tirzepatide's data is newer but growing fast. Neither is an evidence risk; semaglutide simply has more history.
Side effects
Both lists are dominated by GI effects — nausea, constipation, diarrhea — that cluster during dose escalation. Trial discontinuation rates were broadly similar. Individual tolerance differs and isn't predictable in advance.
Cost and access
Both are expensive brand drugs whose out-of-pocket reality depends on insurance, savings programs and indication. Which one a plan covers is frequently the deciding factor in practice — a coverage question, not a science question.
The bottom line
Tirzepatide produced larger average weight loss in the head-to-head trial; semaglutide carries the longer track record and cardiovascular-outcomes data. Both are legitimate, well-evidenced prescription medicines — which one fits a given patient is a prescriber-and-insurance conversation, not a forum verdict.
Semaglutide vs. Tirzepatide FAQ
More comparisons
Tirzepatide vs. Retatrutide
One is an FDA-approved medicine; the other is an investigational triple agonist still in trials. The comparison that matters is regulatory status, not receptor count.
Semaglutide vs. Liraglutide
Two generations of the same drug class: how the weekly GLP-1 compares with its daily predecessor on results, track record and — increasingly — cost.
BPC-157 vs. TB-500
The internet's two favorite healing peptides compared honestly: different molecules, similar marketing, and the same missing ingredient — controlled human trials.
Build your own comparison